The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Wall Street Called Lower Ahead Of Data

Wed, 05th Feb 2014 13:06

LONDON (Alliance News) - US stocks are called to open in negative territory Wednesday, having closed firmly higher Tuesday, as investors take a step back ahead of a raft of US macro-economic data.

Wall Street shook off recent weaknesses to close higher Tuesday, with the DJIA closing up 0.5%, the S&P 500 closing up 0.8%, and the Nasdaq Composite closing up 0.9%.

These gains, however, are expected to be short-lived, with stock futures pointing to a slightly lower open Wednesday. The DJIA, Nasdaq Composite, and S&P 500 are all called to open down 0.2%.

"With the January US non-farm payroll figures due on Friday, Wednesday?s ADP private sector employment change release will be scrutinised for any insights," says Jonathan Thomas, senior economist at Lloyds Bank.

While Thomas expects the ADP to show a 192,000 increase in headcounts, consensus forecasts according to FXStreet.com are for a more modest addition of 180,000. The reading revealed an increase of 238,000 people in employment.

However, ?the number may fall on deaf ears regardless of the outcome after December?s report deviated from official payrolls data by a whopping 164,000," warns Ilya Spivak, currency analyst at DailyFX.

"The ISM figure may generate greater interest, but expectations for a pick-up in service-sector activity growth may be disappointed," he adds.

The Institute for Supply Management releases its non-manufacturing PMI report at 1500 GMT. The reading is expected to rise to 53.7 in January, up from December's 53.0 figure.

"Traditionally, the US non-manufacturing series is not seen as important as the manufacturing ISM, but the market will be looking for any indications that the surprise slump in the latter in January was an isolated case rather than representing a broader slowdown; a further downside surprise here would certainly suggest a further cold front for financial markets," says Rabobank analyst Michael Every.

Also in the US data calendar Wednesday, US Markit services PMI is released at 1358 GMT.

There is also a series of Fed-speakers throughout the day. Daniel Tarullo, member of the Board of Governors of the US Federal Reserve Board, speaks at 1500 GMT. Philadelphia Fed President Charles Plosser speaks at 1730 GMT, ahead of Atlanta Fed President Dennis Lockhart at 1840 GMT.

In corporate news, Time Warner Inc has released its fourth quarter results ahead of the New York bell. Earnings per share came in at USD1.17, beating estimates of USD1.15. The company also said it will look to begin a USD5 billion share buy-back programme. Shares in the stock are up 1.4% in pre-market trading.

Meanwhile, Twitter will report its first quarterly results since its 2013 IPO later in the day.

In the UK, stocks trade mixed. The FTSE 100 is currently up 0.3% at 6,470.07, the FTSE 250 is up 0.3% at 15,593.6, while the AIM All-Share is down 0.1% at 856.54.

In the main corporate event of the day, GlaxoSmithKline reported higher fourth quarter profits as new revenues increased and it cut costs. It also confirmed that it expects to launch late stage clinical trials on ten new drugs over the next two years.

The company reported a pretax profit of GBP2.55 billion for the three months to end-December, up from GBP1.73 billion a year earlier, with revenues rising to GBP6.91 billion, from GBP6.80 billion. For the full-year, pretax profit climbed to GBP6.65 billion, from GBP6.60 billion in 2012, as revenues rose to GBP26.51 billion, from GBP26.43 billion.

The results for both the fourth quarter and full-year were in line with analysts' forecasts.

Nevertheless, the pharmaceuticals major is up 2.4% at 1,590.50 pence, placing it amongst the biggest blue-chip riser.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.